BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boeck S, Heinemann V. Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer. J Clin Oncol. 2008;26:1178-119; author reply 1179. [PMID: 18309957 DOI: 10.1200/jco.2007.15.3304] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, Lee SS, Seo DW, Lee SK, Kim MH, Han DJ, Kim SC, Lee JL. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer. 2009;101:1658-1663. [PMID: 19826418 DOI: 10.1038/sj.bjc.6605374] [Cited by in Crossref: 105] [Cited by in F6Publishing: 103] [Article Influence: 8.1] [Reference Citation Analysis]
2 Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, Mazard T, Caillo L, Faure S, Samalin E, Assenat E. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastroenterol 2012; 18(12): 1357-1364 [PMID: 22493549 DOI: 10.3748/wjg.v18.i12.1357] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
3 Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010;7:163-72. [DOI: 10.1038/nrclinonc.2009.236] [Cited by in Crossref: 516] [Cited by in F6Publishing: 504] [Article Influence: 43.0] [Reference Citation Analysis]
4 Heinemann V. Internistisch-onkologische Aspekte bei der Behandlung des Pankreaskarzinoms. Radiologe 2009;49:144-8. [DOI: 10.1007/s00117-008-1753-3] [Reference Citation Analysis]
5 Sarabi M, Mais L, Oussaid N, Desseigne F, Guibert P, De La Fouchardiere C. Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma. Oncol Lett. 2017;13:4917-4924. [PMID: 28599496 DOI: 10.3892/ol.2017.6061] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
6 Akita H, Zheng Z, Takeda Y, Kim C, Kittaka N, Kobayashi S, Marubashi S, Takemasa I, Nagano H, Dono K, Nakamori S, Monden M, Mori M, Doki Y, Bepler G. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene. 2009;28:2903-2909. [PMID: 19543324 DOI: 10.1038/onc.2009.158] [Cited by in Crossref: 84] [Cited by in F6Publishing: 82] [Article Influence: 6.5] [Reference Citation Analysis]
7 Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009;27:193-198. [PMID: 19047305 DOI: 10.1200/jco.2008] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009;27:193-198. [PMID: 19047305 DOI: 10.1200/jco.2008.18.9514] [Cited by in Crossref: 187] [Cited by in F6Publishing: 115] [Article Influence: 13.4] [Reference Citation Analysis]
9 Carvajal RD, Tse A, Shah MA, Lefkowitz RA, Gonen M, Gilman-Rosen L, Kortmansky J, Kelsen DP, Schwartz GK, O’Reilly EM. A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer. Pancreatology. 2009;9:404-409. [PMID: 19451750 DOI: 10.1159/000187135] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
10 Lee JE, Lee HS, Chung MJ, Park JY, Park SW, Song SY, Bang S. Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer. Gut Liver 2020;14:135-43. [PMID: 30974927 DOI: 10.5009/gnl18419] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]